These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 11164187)
21. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929 [TBL] [Abstract][Full Text] [Related]
22. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Keller C; Arenkiel BR; Coffin CM; El-Bardeesy N; DePinho RA; Capecchi MR Genes Dev; 2004 Nov; 18(21):2614-26. PubMed ID: 15489287 [TBL] [Abstract][Full Text] [Related]
23. Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube. Finckenstein FG; Davicioni E; Osborn KG; Cavenee WK; Arden KC; Anderson MJ Transgenic Res; 2006 Oct; 15(5):595-614. PubMed ID: 16952014 [TBL] [Abstract][Full Text] [Related]
24. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma. Bennicelli JL; Advani S; Schäfer BW; Barr FG Oncogene; 1999 Jul; 18(30):4348-56. PubMed ID: 10439042 [TBL] [Abstract][Full Text] [Related]
25. Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Lagutina I; Conway SJ; Sublett J; Grosveld GC Mol Cell Biol; 2002 Oct; 22(20):7204-16. PubMed ID: 12242297 [TBL] [Abstract][Full Text] [Related]
26. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin. Keller C; Hansen MS; Coffin CM; Capecchi MR Genes Dev; 2004 Nov; 18(21):2608-13. PubMed ID: 15520281 [TBL] [Abstract][Full Text] [Related]
27. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Khan J; Bittner ML; Saal LH; Teichmann U; Azorsa DO; Gooden GC; Pavan WJ; Trent JM; Meltzer PS Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13264-9. PubMed ID: 10557309 [TBL] [Abstract][Full Text] [Related]
28. Detection of PAX3-FKHR and PAX7-FKHR fusion transcripts in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction using paraffin-embedded tissue. Chen BF; Chen ML; Liang DC; Huang YW; Liu HC; Chen SH Zhonghua Yi Xue Za Zhi (Taipei); 1999 Feb; 62(2):86-91. PubMed ID: 10063718 [TBL] [Abstract][Full Text] [Related]
29. New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. Keller C; Capecchi MR Cancer Res; 2005 Sep; 65(17):7530-2. PubMed ID: 16140913 [TBL] [Abstract][Full Text] [Related]
30. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Epstein JA; Song B; Lakkis M; Wang C Mol Cell Biol; 1998 Jul; 18(7):4118-30. PubMed ID: 9632796 [TBL] [Abstract][Full Text] [Related]
31. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. Barr FG; Nauta LE; Davis RJ; Schäfer BW; Nycum LM; Biegel JA Hum Mol Genet; 1996 Jan; 5(1):15-21. PubMed ID: 8789435 [TBL] [Abstract][Full Text] [Related]
32. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Lam PY; Sublett JE; Hollenbach AD; Roussel MF Mol Cell Biol; 1999 Jan; 19(1):594-601. PubMed ID: 9858583 [TBL] [Abstract][Full Text] [Related]
33. Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions. Collins MH; Zhao H; Womer RB; Barr FG Med Pediatr Oncol; 2001 Aug; 37(2):83-9. PubMed ID: 11496344 [TBL] [Abstract][Full Text] [Related]
35. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Ahn EH Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752 [TBL] [Abstract][Full Text] [Related]
36. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427 [TBL] [Abstract][Full Text] [Related]
37. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein. Ayalon D; Glaser T; Werner H Growth Horm IGF Res; 2001 Oct; 11(5):289-97. PubMed ID: 11735247 [TBL] [Abstract][Full Text] [Related]
38. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Linardic CM; Naini S; Herndon JE; Kesserwan C; Qualman SJ; Counter CM Cancer Res; 2007 Jul; 67(14):6691-9. PubMed ID: 17638879 [TBL] [Abstract][Full Text] [Related]
39. The Pax3-FKHR oncoprotein is unresponsive to the Pax3-associated repressor hDaxx. Hollenbach AD; Sublett JE; McPherson CJ; Grosveld G EMBO J; 1999 Jul; 18(13):3702-11. PubMed ID: 10393185 [TBL] [Abstract][Full Text] [Related]
40. [Influences of PAX3-FKHR transfection on expression of MRF4 and differentiation of cultured human rhabdomyosarcoma RD cells]. Li GH; Wang DL; Wang Y; Chen ZT; Li DZ Ai Zheng; 2003 Jan; 22(1):30-4. PubMed ID: 12561432 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]